3-Month Discontinuation of Dual Antiplatelet Therapy After Ultimaster Sirolimus-Eluting Stent Implantation
NCT ID: NCT02837003
Last Updated: 2016-08-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1500 participants
OBSERVATIONAL
2016-07-31
2019-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Additionally to investigate appropriateness of thienopyridine monotherapy with discontinuation of aspirin.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation
NCT00822536
Study of Antiplatelet Therapy for Intracranial Aneurysm Stent-assisted Coiling
NCT02224131
Optimized Antiplatelet Therapy on the Prognosis of ACS Patients With Non-predominant Coronary Artery Disease After PCI
NCT04338919
Synergy Between Stent and Drugs to Avoid Ischemic Recurrences After Percutaneous Coronary Intervention
NCT00611286
Optimal PERioperative Antiplatelet Therapy Investigation ON Abdominal Surgery After Coronary Stent Implantation
NCT06723145
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental: Aspirin
Aspirin treatment for 3 months after the Ultimaster sirolimus-eluting stent implantation.
Aspirin
Discontinuation of aspirin at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
Experimental: Thienopyridine
Thienopyridine treatment for 3 months after the Ultimaster sirolimus-eluting Stent implantation.
Thienopyridine
Discontinuation of thienopyridine at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aspirin
Discontinuation of aspirin at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
Thienopyridine
Discontinuation of thienopyridine at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients considered appropriate to discontinue dual antiplatelet therapy at 3 months after stent implantation.
* Patients who have provided written informed consent.
Exclusion Criteria
* Patients who are unable to clinical follow-up procedure specified in the protocal for the present study.
* Patients who are enrolled or planned to participate in another clinical trials of antiplatelet therapy.
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Teikyo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ken Kozuma, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Teikyo University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Teikyo University Hospital
Tokyo, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MODEL U-SES
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.